- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05363631
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)
Study Overview
Status
Intervention / Treatment
Detailed Description
The proposed study is a single arm, open-label Phase I/II trial of Seleno-L Methionine (SLM) in sequential combination with the standard dose and schedule of Axitinib and Pembrolizumab in previously untreated patients with advanced ccRCC. The hypothesis is that adding SLM to the Pembrolizumab and Axitinib combination will improve efficacy without added toxicity.
This is a two-part study:
- Escalation Part 1: The study will begin with a dose-escalation study to find the maximum tolerated dose (MTD) of study drug, SLM.
- Expansion Part 2: Once the appropriate dose of SLM is determined, the second part of the study will begin.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals & Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
To be eligible to participate in this study, an individual must meet all the following criteria:
- Written and voluntary informed consent.
- Histologically and radiologically confirmed locally advanced or metastatic ccRCC. Locally advanced is defined as non resectable in the opinion of the treating providers. Participants must be treatment naïve in metastatic setting. Prior immunotherapy treatment in adjuvant setting is allowed.
- > 18 years of age
- At least one Response Evaluation Criteria in Solid Tumors (RECIST 1.1)-defined target lesion that has not been irradiated
- Eastern Cooperative Oncology Group performance status of 0 (fully active, able to carry on all pre-disease performance without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work).
- Renal function (creatinine level within normal institutional limit, or creatinine clearance >15 mL/min/1.73 m2 for patients with creatinine levels above institutional normal, calculated using the Cockcroft-Gault formula).
- Liver function (AST/ALT <3.0 X institutional upper limit of normal OR < 5 x institutional upper limit of normal in cases of liver metastases; Total bilirubin ≤ 1.5 times ULN.)
Adequate hematological lab values including
- Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
- Platelets ≥ 100 x 109/L
- Hemoglobin ≥ 7.0 g/dL
- Has adequately controlled BP with or without antihypertensive medications, defined as BP ≤150/90 mm Hg with no change in antihypertensive medications within 1 week before randomization/allocation.
- Female subjects of childbearing potential and non-sterilized male subjects who intend to be sexually active during the study must agree to use a highly effective method of contraception from the time of screening, throughout the total duration of the drug treatment, and during the 6 month post-drug washout period. See section 5.6 for full details.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Patients with a prior or concurrent malignancy whose natural history or treatment may have the potential to interfere with the safety or efficacy assessment of the investigational regimen.
- Untreated metastases in the central nervous system.
- Pregnant or breastfeeding.
- Present use or anticipated need for cytochrome P450 (CYP) 3A4-inhibiting, CYP3A4-inducing drugs (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole, rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, and St. John's wort, bosentan, efavirenz, etravirine, modafinil, and nafcillin).
- Myocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous 6 months. Participants with history of deep vein thrombosis or pulmonary embolism, at provider discretion.
- Major surgery within 4 weeks of starting study treatment.
- Patients with HIV infection with CD4+ T-cell (CD4+) counts < 350 cells/uL
- Patients with HIV infection and a history of AIDS-defining opportunistic infections
No exclusions will be made based on sex, race, or ethnic background.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Seleno-L Methionine (SLM) in Combination with Axitinib and Pembrolizumab
SLM only will be taken by mouth during a two-week run in period.
Then patients will receive SLM and Axitinib drugs by mouth, and Pembrolizumab intravenously (IV), at the start of each 21 day cycle.
|
Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds.
Humans get their dietary requirements mainly from food.
In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
Axitinib is a small molecule tyrosine kinase inhibitor.
Pembrolizumab is a type of immunotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase I - Dose limiting toxicities using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time Frame: From the initiation of treatment through three years
|
To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients
|
From the initiation of treatment through three years
|
|
Phase II - Objective Response Rate (ORR)
Time Frame: From the initiation of treatment through three years
|
ORR will be defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1
|
From the initiation of treatment through three years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival (PFS)
Time Frame: From the initiation of treatment through three years
|
PFS will be defined as the time from treatment initiation to the date of first documentation of disease progression or death due to any cause
|
From the initiation of treatment through three years
|
|
Overall survival (OS)
Time Frame: From the initiation of treatment through three years
|
OS will be defined as the time from treatment initiation to the date of death due to any cause
|
From the initiation of treatment through three years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mohammed Milhem, MD, University of Iowa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Urologic Neoplasms
- Carcinoma
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Clear-cell metastatic renal cell carcinoma
- Amino Acids, Peptides, and Proteins
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Azoles
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carboxylic Acids
- Hydrocarbons, Aromatic
- Amides
- Amino Acids
- Benzene Derivatives
- Acids, Carbocyclic
- Amino Acids, Sulfur
- Benzoates
- Benzamides
- Indazoles
- Pyrazoles
- Methionine
- Organoselenium Compounds
- Axitinib
- pembrolizumab
- Selenomethionine
Other Study ID Numbers
- 202104398
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.